H. Lundbeck, Bifeprunox enters clinical phase III

H. Lundbeck A/S and Solvay Pharmaceuticals today announce their joint decision to move bifeprunox into clinical phase III with immediate effect.  The decision to move into phase III follows the successful completion of the joint phase II program. In December 2000 the two companies announced that they would join forces in the development and marketing of this atypical antipsychotic, bifeprunox.